Citations (46)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (5)
Xiaoming Ouyang, Ashley Barling, Aletha Lesch, Jeffrey W. Tyner, Gabrielle Choonoo, Christina Zheng, Sophia Jeng, Toni M. West, Daniel Clayburgh, Sara A. Courtneidge, Shannon K. McWeeney & Molly Kulesz-Martin. (2018) Induction of anaplastic lymphoma kinase (ALK) as a novel mechanism of EGFR inhibitor resistance in head and neck squamous cell carcinoma patient-derived models. Cancer Biology & Therapy 19:10, pages 921-933.
Read now
Read now
Francesca Farina, Alessandra Stasia & Carlo Gambacorti-Passerini. (2014) Developments in anaplastic large-cell lymphoma: targeting the anaplastic lymphoma kinase. Blood and Lymphatic Cancer: Targets and Therapy 4, pages 69-79.
Read now
Read now
Aswin Somasundaram, Mark A Socinski & Timothy F Burns. (2014) Personalized treatment of EGFR mutant and ALK-positive patients in NSCLC. Expert Opinion on Pharmacotherapy 15:18, pages 2693-2708.
Read now
Read now
Eugen F Mesaros, Gregory R Ott & Bruce D Dorsey. (2014) Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review. Expert Opinion on Therapeutic Patents 24:4, pages 417-442.
Read now
Read now
Renato Franco, Gaetano Rocco, Federica Zito Marino, Giuseppe Pirozzi, Nicola Normanno, Alessandro Morabito, Pasquale Sperlongano, Paola Stiuso, Amalia Luce, Gerardo Botti & Michele Caraglia. (2013) Anaplastic lymphoma kinase: a glimmer of hope in lung cancer treatment?. Expert Review of Anticancer Therapy 13:4, pages 407-420.
Read now
Read now
Articles from other publishers (41)
Zhen Li, Fang Liu, Shuang Wu, Shi Ding, Ye Chen & Ju Liu. (2022) Research Progress on the Drug Resistance of ALK Kinase Inhibitors. Current Medicinal Chemistry 29:14, pages 2456-2475.
Crossref
Crossref
Matteo Villa, Geeta G. Sharma, Chiara Manfroni, Diego Cortinovis & Luca Mologni. (2021) New Advances in Liquid Biopsy Technologies for Anaplastic Lymphoma Kinase (ALK)—Positive Cancer. Cancers 13:20, pages 5149.
Crossref
Crossref
Estelle Espinos, Raymond Lai & Sylvie Giuriato. (2021) The Dual Role of Autophagy in Crizotinib-Treated ALK+ ALCL: From the Lymphoma Cells Drug Resistance to Their Demise. Cells 10:10, pages 2517.
Crossref
Crossref
Nilesh D. Parmar, Sanjay D. Hadiyal, Vimal H. Kapupara, Jaydeep N. Lalpara & Hitendra S. Joshi. (2021) Synthesis of new tetrahydropyridopyrazine derivatives via continuous flow chemistry approach and their spectroscopic characterizations. Journal of Heterocyclic Chemistry 58:7, pages 1437-1445.
Crossref
Crossref
Alexandra Giannaki, Dimitrios Doganis, Panagiota Giamarelou & Anastasia Konidari. (2021) Epithelioid Inflammatory Myofibroblastic Sarcoma Presenting as Gastrointestinal Bleed: Case Report and Literature Review. JPGN Reports 2:1, pages e019.
Crossref
Crossref
Nicole L. Michmerhuizen, Jiayu Wang & J. Chad Brenner. 2020. Molecular Pharmacology. Molecular Pharmacology.
Domenico Sorrentino, Julie Frentzel, Géraldine Mitou, Rafael B. Blasco, Avédis Torossian, Coralie Hoareau-Aveilla, Chiara Pighi, Manon Farcé, Fabienne Meggetto, Stéphane Manenti, Estelle Espinos, Roberto Chiarle & Sylvie Giuriato. (2020) High Levels of miR-7-5p Potentiate Crizotinib-Induced Cytokilling and Autophagic Flux by Targeting RAF1 in NPM-ALK Positive Lymphoma Cells. Cancers 12:10, pages 2951.
Crossref
Crossref
Dong-Jun Fu, Yun-Feng Zhang, An-Qi Chang & Jun Li. (2020) β-Lactams as promising anticancer agents: Molecular hybrids, structure activity relationships and potential targets. European Journal of Medicinal Chemistry 201, pages 112510.
Crossref
Crossref
Hong Chen, Ridong Li, Xianling Ning, Xuyang Zhao, Yan Jin & Yuxin Yin. (2019) Synthesis and anti-tumor efficacy of novel 2, 4-diarylaminopyrimidine derivatives bearing N-(3-pyridinylmethyl) urea moiety as anaplastic lymphoma kinase inhibitors. European Journal of Medicinal Chemistry 178, pages 141-153.
Crossref
Crossref
Qianting Zhang, Mu Xiao, Shuchen Gu, Yongxian Xu, Ting Liu, Hao Li, Yi Yu, Lan Qin, Yezhang Zhu, Fenfang Chen, Yulong Wang, Chen Ding, Hongxing Wu, Hongbin Ji, Zhe Chen, Youli Zu, Stephen Malkoski, Yi Li, Tingbo Liang, Junfang Ji, Jun Qin, Pinglong Xu, Bin Zhao, Li Shen, Xia Lin & Xin-Hua Feng. (2019) ALK phosphorylates SMAD4 on tyrosine to disable TGF-β tumour suppressor functions. Nature Cell Biology 21:2, pages 179-189.
Crossref
Crossref
Jing Tu, Li Ting Song, Rui Rui Liu, Hong Lin Zhai, Juan Wang & Xiao Yun Zhang. (2018) Molecular inhibitory mechanism study on the potent inhibitor brigatinib against four crizotinib‐resistant ALK mutations. Journal of Cellular Biochemistry 120:1, pages 562-574.
Crossref
Crossref
Sara Redaelli, Monica Ceccon, Marina Zappa, Geeta G. Sharma, Cristina Mastini, Mario Mauri, Marion Nigoghossian, Luca Massimino, Nicoletta Cordani, Francesca Farina, Rocco Piazza, Carlo Gambacorti-Passerini & Luca Mologni. (2018) Lorlatinib Treatment Elicits Multiple On- and Off-Target Mechanisms of Resistance in ALK-Driven Cancer. Cancer Research 78:24, pages 6866-6880.
Crossref
Crossref
Jing Tu, Li Ting Song, Hong Lin Zhai, Juan Wang & Xiao Yun Zhang. (2018) Selective mechanisms and molecular design of 2,4 Diarylaminopyrimidines as ALK inhibitors. International Journal of Biological Macromolecules 118, pages 1149-1156.
Crossref
Crossref
Silky Bedi, Shah A. Khan, Majed M. AbuKhader, Perwez Alam, Nasir A. Siddiqui & Asif Husain. (2018) A comprehensive review on Brigatinib – A wonder drug for targeted cancer therapy in non-small cell lung cancer. Saudi Pharmaceutical Journal 26:6, pages 755-763.
Crossref
Crossref
Julie Frentzel, Domenico Sorrentino & Sylvie Giuriato. (2017) Targeting Autophagy in ALK-Associated Cancers. Cancers 9:12, pages 161.
Crossref
Crossref
Severine Cao & Vinod Nambudiri. (2017) Anaplastic Lymphoma Kinase in Cutaneous Malignancies. Cancers 9:12, pages 123.
Crossref
Crossref
Ailbhe C. O'NeillJyothi P. JagannathanNikhil H. Ramaiya. (2017) Evolving Cancer Classification in the Era of Personalized Medicine: A Primer for Radiologists. Korean Journal of Radiology 18:1, pages 6.
Crossref
Crossref
Jad A Degheili, Nadim A Kanj, Salwa A Koubaissi & Mouhamad J Nasser. (2017) Indolent lung opacity: Ten years follow-up of pulmonary inflammatory pseudo-tumor. World Journal of Clinical Cases 5:2, pages 61.
Crossref
Crossref
M Ceccon, M E Boggio Merlo, L Mologni, T Poggio, L M Varesio, M Menotti, S Bombelli, R Rigolio, A D Manazza, F Di Giacomo, C Ambrogio, G Giudici, C Casati, C Mastini, M Compagno, S D Turner, C Gambacorti-Passerini, R Chiarle & C Voena. (2015) Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency. Oncogene 35:29, pages 3854-3865.
Crossref
Crossref
P Vicini, O Fields, E Lai, ED Litwack, A-M Martin, TM Morgan, MA Pacanowski, M Papaluca, OD Perez, MS Ringel, M Robson, H Sakul, J Vockley, T Zaks, M Dolsten & M Søgaard. (2016) Precision medicine in the age of big data: The present and future role of large-scale unbiased sequencing in drug discovery and development. Clinical Pharmacology & Therapeutics 99:2, pages 198-207.
Crossref
Crossref
Coralie Hoareau-Aveilla, Thibaud Valentin, Camille Daugrois, Cathy Quelen, Géraldine Mitou, Samuel Quentin, Jinsong Jia, Salvatore Spicuglia, Pierre Ferrier, Monica Ceccon, Sylvie Giuriato, Carlo Gambacorti-Passerini, Pierre Brousset, Laurence Lamant & Fabienne Meggetto. (2015) Reversal of microRNA-150 silencing disadvantages crizotinib-resistant NPM-ALK(+) cell growth. Journal of Clinical Investigation 125:9, pages 3505-3518.
Crossref
Crossref
Ryoji Kobayashi, Shosuke Sunami, Tetsuo Mitsui, Atsuko Nakazawa, Yuhki Koga, Takeshi Mori, Fumiko Tanaka, Jun-ichi Ueyama, Tomoo Osumi, Reiji Fukano, Kentaro Ohki, Masahiro Sekimizu & Tetsuya Mori. (2015) Treatment of pediatric lymphoma in Japan: Current status and plans for the future. Pediatrics International 57:4, pages 523-534.
Crossref
Crossref
S. Carnesecchi, A.-L. Rougemont, J.H. Doroshow, M. Nagy, S. Mouche, F. Gumy-Pause & I. Szanto. (2015) The NADPH oxidase NOX5 protects against apoptosis in ALK-positive anaplastic large-cell lymphoma cell lines. Free Radical Biology and Medicine 84, pages 22-29.
Crossref
Crossref
Diletta Fontana, Monica Ceccon, Carlo Gambacorti-Passerini & Luca Mologni. (2015) Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK. Cancer Medicine 4:7, pages 953-965.
Crossref
Crossref
M. Ceccon, L. Mologni, G. Giudici, R. Piazza, A. Pirola, D. Fontana & C. Gambacorti-Passerini. (2015) Treatment Efficacy and Resistance Mechanisms Using the Second-Generation ALK Inhibitor AP26113 in Human NPM-ALK–Positive Anaplastic Large Cell Lymphoma. Molecular Cancer Research 13:4, pages 775-783.
Crossref
Crossref
Luca Mologni, Monica Ceccon, Alessandra Pirola, Gianpaolo Chiriano, Rocco Piazza, Leonardo Scapozza & Carlo Gambacorti-Passerini. (2015) NPM/ALK mutants resistant to ASP3026 display variable sensitivity to alternative ALK inhibitors but succumb to the novel compound PF-06463922. Oncotarget 6:8, pages 5720-5734.
Crossref
Crossref
Zilan Song, Yanhong Yang, Zhiqing Liu, Xia Peng, Junfeng Guo, Xinying Yang, Kui Wu, Jing Ai, Jian Ding, Meiyu Geng & Ao Zhang. (2014) Discovery of Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent Inhibitory Activities against Both Wild-type and Mutant ALK Kinases. Journal of Medicinal Chemistry 58:1, pages 197-211.
Crossref
Crossref
Esperanza Martín-Sánchez, Lina Odqvist, Socorro M. Rodríguez-Pinilla, Margarita Sánchez-Beato, Giovanna Roncador, Beatriz Domínguez-González, Carmen Blanco-Aparicio, Ana M. García Collazo, Esther González Cantalapiedra, Joaquín Pastor Fernández, Soraya Curiel del Olmo, Helena Pisonero, Rebeca Madureira, Carmen Almaraz, Manuela Mollejo, F. Javier Alves, Javier Menárguez, Fernando González-Palacios, José Luis Rodríguez-Peralto, Pablo L. Ortiz-Romero, Francisco X. Real, Juan F. García, James R. Bischoff & Miguel A. Piris. (2014) PIM Kinases as Potential Therapeutic Targets in a Subset of Peripheral T Cell Lymphoma Cases. PLoS ONE 9:11, pages e112148.
Crossref
Crossref
Zhiqing Liu, Xihua Yue, Zilan Song, Xia Peng, Junfeng Guo, Yinchun Ji, Zhen Cheng, Jian Ding, Jing Ai, Meiyu Geng & Ao Zhang. (2014) Design, synthesis and pharmacological evaluation of 2-(thiazol-2-amino)-4-arylaminopyrimidines as potent anaplastic lymphoma kinase (ALK) inhibitors. European Journal of Medicinal Chemistry 86, pages 438-448.
Crossref
Crossref
Nicholas C. Nicolaides, Daniel J. O’Shannessy, Earl Albone & Luigi Grasso. (2014) Co-Development of Diagnostic Vectors to Support Targeted Therapies and Theranostics: Essential Tools in Personalized Cancer Therapy. Frontiers in Oncology 4.
Crossref
Crossref
Zhiqing Liu, Jing Ai, Xia Peng, Zilan Song, Kui Wu, Jing Zhang, Qizheng Yao, Yi Chen, Yinchun Ji, Yanhong Yang, Meiyu Geng & Ao Zhang. (2014) Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities. ACS Medicinal Chemistry Letters 5:4, pages 304-308.
Crossref
Crossref
Jiang Wang, María Sánchez-Roselló, José Luis Aceña, Carlos del Pozo, Alexander E. Sorochinsky, Santos Fustero, Vadim A. Soloshonok & Hong Liu. (2013) Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011). Chemical Reviews 114:4, pages 2432-2506.
Crossref
Crossref
Sébastien Tardy, Alexandre Orsato, Luca Mologni, William H. Bisson, Carla Donadoni, Carlo Gambacorti-Passerini, Leonardo Scapozza, David Gueyrard & Peter G. Goekjian. (2014) Synthesis and biological evaluation of benzo[4,5]imidazo[1,2-c]pyrimidine and benzo[4,5]imidazo[1,2-a]pyrazine derivatives as anaplastic lymphoma kinase inhibitors. Bioorganic & Medicinal Chemistry 22:4, pages 1303-1312.
Crossref
Crossref
Mustapha El Amrani, Daowan Lai, Abdessamad Debbab, Amal H. Aly, Karsten Siems, Carole Seidel, Michael Schnekenburger, Anthoula Gaigneaux, Marc Diederich, Daniel Feger, Wenhan Lin & Peter Proksch. (2013)
Protein Kinase and HDAC Inhibitors from the Endophytic Fungus
Epicoccum nigrum
. Journal of Natural Products 77:1, pages 49-56.
Crossref
Crossref
Mark R. Wick, Oscar Nappi & John D. Pfeifer. (2013) Molecular techniques in anatomic pathology: An overview. Seminars in Diagnostic Pathology 30:4, pages 263-283.
Crossref
Crossref
Andrew L. Feldman, George Vasmatzis, Yan W. Asmann, Jaime Davila, Sumit Middha, Bruce W. Eckloff, Sarah H. Johnson, Julie C. Porcher, Stephen M. Ansell & Ariel Caride. (2013)
Novel
TRAF1-ALK
fusion identified by deep RNA sequencing of anaplastic large cell lymphoma
. Genes, Chromosomes and Cancer 52:11, pages 1097-1102.
Crossref
Crossref
Antonino Carbone & Anas YounesMeghan KaruturiAnas Younes. 2013. Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies. Non-Hodgkin Lymphomas: Advanced Diagnostics & Personalized Therapies
124
136
.
Srishma Sridhar, Batool Al-Moallem, Hawra Kamal, Marta Terrile & Raymond L. Stallings. (2013) New Insights into the Genetics of Neuroblastoma. Molecular Diagnosis & Therapy 17:2, pages 63-69.
Crossref
Crossref
Ewa B. Bajor-Dattilo, Stefania Pittaluga & Elaine S. Jaffe. (2013) Pathobiology of T-cell and NK-cell lymphomas. Best Practice & Research Clinical Haematology 26:1, pages 75-87.
Crossref
Crossref
Ryouichi Horie. (2013) Molecularly-Targeted Strategy and NF-^|^kappa;B in Lymphoid Malignancies. Journal of Clinical and Experimental Hematopathology 53:3, pages 185-195.
Crossref
Crossref
Fredika M. Robertson & Massimo Cristofanilli. (2012) New Therapeutic Targets in Inflammatory Breast Cancer. Current Breast Cancer Reports 4:4, pages 264-270.
Crossref
Crossref